MA45721A - Procédés de purification de protéines contenant des fragments fc - Google Patents

Procédés de purification de protéines contenant des fragments fc

Info

Publication number
MA45721A
MA45721A MA045721A MA45721A MA45721A MA 45721 A MA45721 A MA 45721A MA 045721 A MA045721 A MA 045721A MA 45721 A MA45721 A MA 45721A MA 45721 A MA45721 A MA 45721A
Authority
MA
Morocco
Prior art keywords
fragments
processes
protein containing
purifying protein
purifying
Prior art date
Application number
MA045721A
Other languages
English (en)
French (fr)
Inventor
John K Kawooya
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA45721A publication Critical patent/MA45721A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • B01D15/3809Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/42Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424Elution mode
    • B01D15/426Specific type of solvent
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/34Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Storage Device Security (AREA)
MA045721A 2016-07-22 2017-07-21 Procédés de purification de protéines contenant des fragments fc MA45721A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662365943P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
MA45721A true MA45721A (fr) 2019-05-29

Family

ID=59656168

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045721A MA45721A (fr) 2016-07-22 2017-07-21 Procédés de purification de protéines contenant des fragments fc

Country Status (12)

Country Link
US (1) US11312745B2 (https=)
EP (1) EP3487867B1 (https=)
JP (2) JP7092744B2 (https=)
KR (2) KR102579850B1 (https=)
CN (2) CN115925780B (https=)
AU (2) AU2017298984B2 (https=)
CA (2) CA3218290A1 (https=)
IL (2) IL285146B (https=)
MA (1) MA45721A (https=)
MX (2) MX2019000903A (https=)
SG (1) SG11201900573UA (https=)
WO (1) WO2018018011A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102713TA (en) * 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
JP7644706B2 (ja) * 2018-10-11 2025-03-12 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
AU2020208360B2 (en) * 2019-01-16 2025-05-08 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying antibody fragmentation
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN112881675A (zh) * 2019-11-29 2021-06-01 广东菲鹏生物有限公司 IgM抗体检测稀释液
JP2023521384A (ja) 2020-04-09 2023-05-24 シートムエックス セラピューティクス,インコーポレイテッド 活性化可能抗体を含む組成物
WO2022061035A1 (en) * 2020-09-16 2022-03-24 Waters Technologies Corporation Improved size exclusion chromatography utilizing low concentration amino acids in size exclusion chromatography mobile phase
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法
CN116165290B (zh) * 2021-12-17 2025-06-27 复旦大学 一种抗体药物研发流程中工程细胞株的筛选方法
CN116271982B (zh) * 2022-11-30 2024-01-09 杭州广科安德生物科技有限公司 一种血液高丰度蛋白免疫亲和柱的再生方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
CA2325022A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2005299716B2 (en) * 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
ZA200710330B (en) * 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
WO2007081906A2 (en) * 2006-01-06 2007-07-19 Amgen Inc. Purification by column-chromatography using eluants containing organic solvents
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008036600A2 (en) * 2006-09-18 2008-03-27 Genentech, Inc. Methods of protein production
JP5522723B2 (ja) 2007-05-21 2014-06-18 ノマディックバイオサイエンス株式会社 新規ポリペプチド,アフィニティークロマトグラフィー用材,及びイムノグロブリンの分離及び/又は精製方法
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
SG2013061528A (en) 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
EP3366692A1 (en) * 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
AU2010266093B2 (en) * 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
CN102382190B (zh) * 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
US20130317172A1 (en) 2010-12-24 2013-11-28 Nomadic Bioscience Co., Ltd. Method for immobilizing temperature responsive protein a
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
EP2831096B1 (en) 2012-03-28 2020-04-29 GE Healthcare BioProcess R&D AB Affinity chromatography matrix
JP6253584B2 (ja) 2012-08-27 2017-12-27 旭化成メディカル株式会社 温度応答性クロマトグラフィーによる抗体の精製方法
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
JP2016538275A (ja) * 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ, エセ.アー. T細胞再標的化ヘテロ二量体免疫グロブリン(hetero−dimeric immunoglobulin)の製造

Also Published As

Publication number Publication date
EP3487867A2 (en) 2019-05-29
CN115925780A (zh) 2023-04-07
KR20220120716A (ko) 2022-08-30
US20190127418A1 (en) 2019-05-02
CA3218290A1 (en) 2018-01-25
IL264375A (en) 2019-02-28
IL285146B (en) 2022-09-01
CA3031469C (en) 2025-11-18
IL264375B (en) 2021-09-30
US11312745B2 (en) 2022-04-26
SG11201900573UA (en) 2019-02-27
AU2017298984A1 (en) 2019-02-07
AU2023222915A1 (en) 2023-09-21
MX2019000903A (es) 2019-05-15
CN109563125A (zh) 2019-04-02
MX2023006291A (es) 2023-06-13
JP7411020B2 (ja) 2024-01-10
EP3487867B1 (en) 2026-04-01
AU2017298984B2 (en) 2023-08-31
JP2019528255A (ja) 2019-10-10
KR102435801B1 (ko) 2022-08-25
AU2023222915B2 (en) 2026-01-22
WO2018018011A3 (en) 2018-03-01
JP2022120138A (ja) 2022-08-17
KR20190037247A (ko) 2019-04-05
KR102579850B1 (ko) 2023-09-18
WO2018018011A2 (en) 2018-01-25
JP7092744B2 (ja) 2022-06-28
CN115925780B (zh) 2025-11-04
CA3031469A1 (en) 2018-01-25
IL285146A (en) 2021-08-31
CN109563125B (zh) 2022-08-09

Similar Documents

Publication Publication Date Title
MA45721A (fr) Procédés de purification de protéines contenant des fragments fc
EP3731863A4 (en) ADENO-ASSOCIATED VIRUS CLEANSING PROCEDURES
EP3436473A4 (en) METHOD FOR PURIFYING FC FUSION PROTEINS
EP2953965A4 (en) PROTEIN PURIFICATION PROCESS
EP3990031A4 (en) Adeno-associated virus purification methods
EP3398965A4 (en) METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION
EP2883882A4 (en) PROTEIN PURIFICATION PROCESS
EP3004135A4 (en) PROCESS FOR CLEANING PROTEINS
EP3429615A4 (en) PROCEDURE FOR CLEANING COLLAGEN 7
EP3240804A4 (en) ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
MX392274B (es) Cartuchos utiles en limpieza de soluciones de dialisis.
EP3387023A4 (en) METHOD FOR HYDROCARBON RECOVERY
EP2575847A4 (en) PROCESS FOR PURIFYING POLYPEPTIDES
FR3014901B1 (fr) Procede de purification de virus ou vecteurs viraux enveloppes
FR3025515B1 (fr) Procede de purification d'un anticorps monoclonal
EP3325614A4 (en) PROCESS FOR CLEANING ADENOVIRUS VECTORS
EP2975020A4 (en) PROCESS FOR CLEANING 1,5-DIAMINOPENTANE
EP3466536A4 (en) EMISSION CONTROL CATALYST
EP3434363A4 (en) EMISSION CONTROL CATALYST
DK3416974T3 (da) Proteinoprensning
MA41941A (fr) Procédé de purification de protéines
PL3307996T3 (pl) Układ oczyszczania gazów spalinowych
EP3521299A4 (en) METHOD FOR PURIFYING RECOMBINANT PROTEINS
EP3438426A4 (en) Exhaust purification system
EP3318552A4 (en) PROCESS FOR CLEANING METHIONINE